XASE
MLSS
Market cap29mUSD
Jul 10, Last price
0.38USD
1D
5.19%
1Q
29.04%
Jan 2017
-74.64%
Name
Milestone Scientific Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets. The company's operations are divided into two main segments: Dental and Medical. Within its Dental division, key products include CompuDent and the STA Single Tooth Anesthesia System, both instrumental for delivering local anesthetics across all dental procedures. For broader applications, the firm offers CompuFlo, a sophisticated computer-controlled system capable of delivering drugs, anesthetics, and other medicaments comfortably and precisely, as well as aspirating bodily fluids or prior injections. Complementing this, a disposable injection handpiece provides precise tactile control during administration. In the Medical segment, Milestone Scientific introduces the CompuFlo Epidural, a computer-guided anesthesia system designed for a variety of medical applications. Additionally, their CompuMed system is utilized in numerous specialized procedures, including plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics, among others. Headquartered in Livingston, New Jersey, Milestone Scientific Inc. was established in 1989.
IPO date
Nov 03, 1995
Employees
20
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||